Literature DB >> 21390190

Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas.

Anke Klose1, Yannic Waerzeggers, Parisa Monfared, Slobodan Vukicevic, Eric L Kaijzel, Alexandra Winkeler, Claudia Wickenhauser, Clemens W G M Löwik, Andreas H Jacobs.   

Abstract

Bone morphogenetic protein 7 (BMP-7) belongs to the superfamily of transforming growth factor β-like cytokines, which can act either as tumor suppressors or as tumor promoters depending on cell type and differentiation. Our investigations focused on analyzing the effects of BMP-7 during glioma cell proliferation in vitro and in vivo. BMP-7 treatment decreased the proliferation of Gli36ΔEGFR-LITG glioma cells up to 50%through a cell cycle arrest in the G(1) phase but not by induction of apoptosis. This effect was mediated by the modulation of the expression and phosphorylation of cyclin-dependent kinase 2, cyclin-dependent kinase inhibitor p21, and downstream retinoblastoma protein. Furthermore, in vivo optical imaging of luciferase activity of Gli36ΔEGFR-LITG cells implanted intracranially into nude mice in the presence or absence of BMP-7 treatment corroborated the antiproliferative effects of this cytokine. This report clearly underlines the tumor-suppressive role of BMP-7 in glioma-derived cells. Taken together, our results indicate that manipulating the BMP/transforming growth factor β signaling cascade may serve as a new strategy for imaging-guided molecular-targeted therapy of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390190      PMCID: PMC3050870          DOI: 10.1593/neo.101540

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  41 in total

Review 1.  BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk.

Authors:  Kohei Miyazono; Shingo Maeda; Takeshi Imamura
Journal:  Cytokine Growth Factor Rev       Date:  2005-06       Impact factor: 7.638

2.  Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.

Authors:  Shangxin Yang; Chen Zhong; Baruch Frenkel; A Hari Reddi; Pradip Roy-Burman
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 3.  Role of transforming growth factor Beta in human cancer.

Authors:  Rebecca L Elliott; Gerard C Blobe
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 4.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

Review 5.  Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy.

Authors:  Deborah T Blumenthal; Susan F Schulman
Journal:  Expert Rev Neurother       Date:  2005-09       Impact factor: 4.618

6.  Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.

Authors:  Lene Uhrbom; Edward Nerio; Eric C Holland
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

Review 7.  TGF-beta, neuronal stem cells and glioblastoma.

Authors:  Nady Golestaneh; Bibhuti Mishra
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

8.  BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.

Authors:  Hideyo Miyazaki; Tetsuro Watabe; Tadaichi Kitamura; Kohei Miyazono
Journal:  Oncogene       Date:  2004-12-16       Impact factor: 9.867

Review 9.  TGF-beta signal transduction.

Authors:  J Massagué
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.

Authors:  N Yamada; M Kato; P ten Dijke; H Yamashita; T K Sampath; C H Heldin; K Miyazono; K Funa
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more
  13 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.

Authors:  J Heinke; M Kerber; S Rahner; L Mnich; S Lassmann; T Helbing; M Werner; C Patterson; C Bode; M Moser
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

4.  BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells.

Authors:  Maya Srikanth; Juno Kim; Sunit Das; John A Kessler
Journal:  Mol Cancer Res       Date:  2013-11-22       Impact factor: 5.852

5.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

6.  Genomic Analysis of the BMP Family in Glioblastomas.

Authors:  Laura D Hover; Ty W Abel; Philip Owens
Journal:  Transl Oncogenomics       Date:  2015-04-15

7.  Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma.

Authors:  Pilar González-Gómez; Jose Crecente-Campo; Cristina Zahonero; Maria de la Fuente; Aurelio Hernández-Laín; Helena Mira; Pilar Sánchez-Gómez; Marcos Garcia-Fuentes
Journal:  Oncotarget       Date:  2015-05-10

8.  Gene expression profiling associated with angiotensin II type 2 receptor-induced apoptosis in human prostate cancer cells.

Authors:  Nana Pei; Feilong Jie; Jie Luo; Renqiang Wan; Yanling Zhang; Xinglu Chen; Zhibing Liang; Hongyan Du; Andrew Li; Baihong Chen; Yi Zhang; Colin Sumners; Jinlong Li; Weiwang Gu; Hongwei Li
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 9.  BMPs as therapeutic targets and biomarkers in astrocytic glioma.

Authors:  Pilar González-Gómez; Nilson Praia Anselmo; Helena Mira
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

10.  Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.

Authors:  Jonathan L Tso; Shuai Yang; Jimmy C Menjivar; Kazunari Yamada; Yibei Zhang; Irene Hong; Yvonne Bui; Alexandra Stream; William H McBride; Linda M Liau; Stanley F Nelson; Timothy F Cloughesy; William H Yong; Albert Lai; Cho-Lea Tso
Journal:  Mol Cancer       Date:  2015-11-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.